ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

Abstract Background Most melanoma patients with BRAFV600E positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the treatment. For patients insufficientl...

Cijeli opis

Bibliografski detalji

Glavni autori:	Giulia Cesi, Geoffroy Walbrecq, Andreas Zimmer, Stephanie Kreis, Claude Haan
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2017-06-01
Serija:	Molecular Cancer
Teme:	Melanoma Metabolism RAS/RAF/MEK/ERK pathway NRAS BRAF inhibitors MEK inhibitors
Online pristup:	http://link.springer.com/article/10.1186/s12943-017-0667-y
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!